Side-by-side · Research reference
IpamorelinvsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed21/57 cited
BFDA-ApprovedVerified14/45 cited
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Ipamorelin
Tirzepatide
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002
Glucose-dependent insulin release preserves physiological feedback
Origin
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
Not reported in short-term studies
—
02Dosage Protocols
Parameter
Ipamorelin
Tirzepatide
Standard dose
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
—
Frequency
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
—
Lower / starter dose
100 mcg per dose
—
Evidence basis
Phase 1 + clinical practiceRaun 1998Sigalos 2018
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
Indefinite for chronic indication
Reconstitution
Bacteriostatic water; typical 2 mL per 5 mg vial
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
Pre-sleep + fasted preferred; 30 min away from food
Once weekly, any time of day
Half-life
~2 hoursRaun 1998
Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).
~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
04Side Effects & Safety
Parameter
Ipamorelin
Tirzepatide
Hunger
Mild appetite increase via ghrelin-receptor crosstalk
—
Injection site reaction
Mild irritation possible
Mild erythema, pruritus
GH excess (overdose)
Joint pain, edema, insulin resistance
—
IGF-1 elevation
Dose-dependent; monitor with chronic high-dose use
—
Cancer risk
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Contraindicated
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Ipamorelin
Tirzepatide
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
29–31G, 4–8 mm insulin syringe.
Pen-supplied. Research vial: 27–31G insulin syringe.
06Stack Synergy
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern
Tirzepatide
— no documented stacks